Glenmark Pharma To Conduct Trials For Potential COVID-19 Drug, Shares Jump

Glenmark Pharmaceuticals shares rose almost 9 per cent on Thursday after the drug maker received an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19. Favipiravir, manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.
“After having successfully developed the API and the formulations … Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India,” Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement.

The Drug Controller General of India (DGCI), the country’s drug regulator, did not immediately respond to Reuters request for a comment.

On Wednesday, another pharmaceutical company, Strides Pharma Science, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Be the first to comment

Leave a Reply

Your email address will not be published.